CLINICAL EVIDENCE TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR)

INDUSTRY-LEADING

HEMODYNAMICS

At one year, 89% of patients had none/trace PVL.1

SEE STUDY RESULTS

COMPREHENSIVE

CLINICAL evidence

The Medtronic CoreValve™ Evolut™ Platform is supported by a robust body of clinical evidence.

VIEW SUMMARY OF Trials

EXCELLENT 

PROCEDURAL OUTCOMES

Evolut PRO 30-day results:1

  • 1.7% all-cause mortality
  • 1.7% disabling stroke
  • 11.8% permanent pacemaker

SEE OUTCOMES

PROVEN 

PLATFORM

Studies demonstrate efficacy of the Evolut TAVR Platform.

VIEW DATA
Senior Male

REAL-WORLD  RESULTS

Five-year results demonstrated meaningful treatment for patients with symptomatic severe aortic stenosis.2

VIEW RESULTS
1

Williams, et. al, presented at ACC 2018, 1-year outcomes with the Evolut PRO Self-Expanding Repositionable Transcatheter Aortic Valve with Pericardial Wrap

2

Gerckens U, Tamburino C, Bleiziffer S, et al. Final 5-year clinical and echocardiographic results for treatment of severe aortic stenosis with a self-expanding bioprosthesis from the ADVANCE Study. Eur Heart J. September 21, 2017;38(36):2729-2738.